Connect with us


Glaucoma Drug Gets FDA Approval; Company to Hire 100 Sales Reps




It’s the firm’s ‘single greatest achievement.’

Aerie Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved Rhopressa 0.02% for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.  

The approval decision was made two months ahead of the scheduled Prescription Drug User Fee Act goal date of Feb. 28.

“The approval of once-daily Rhopressa represents the single greatest achievement in Aerie’s history to date, and represents exciting news for patients with open-angle glaucoma or ocular hypertension, and physicians,” said Vicente Anido Jr., chairman and CEO at Aerie. “It is a testament to years of successful research and development and the incredible talents of our dedicated employees, to whom we owe much gratitude.” 

Anido said the company will hire 100 sales representatives early in the first quarter of 2018.


The company said Rhopressa (netarsudil ophthalmic solution) 0.02% “is believed to reduce IOP by increasing the outflow of aqueous humor (the fluid inside the eye) through the trabecular meshwork, the main fluid drain of the eye.”


Meet the Next Generation of Smart Glasses

Ray-Ban Meta is now available with a full range of lenses, as a complete pair or edged lens. Prescription orders eligible through select insurance providers, including Eyemed and private pay. The Ray-Ban Meta collection combines iconic design with cutting-edge technology. Capture life’s best moments and livestream to Facebook and Instagram with an upgraded 12 MP camera and five-mic system. Stay connected with hands-free calls and messages. Listen to your favorite tracks through built-in speakers. Spark your creativity, get information and control your glasses with your voice – powered by Meta AI. All while keeping your phone in your pocket. For more information, visit here.

Promoted Headlines

Most Popular